14.63
-0.13 (-0.88%)
| Previous Close | 14.76 |
| Open | 14.74 |
| Volume | 753,892 |
| Avg. Volume (3M) | 2,205,729 |
| Market Cap | 1,493,913,216 |
| Price / Book | 11.55 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Diluted EPS (TTM) | -9.25 |
| Total Debt/Equity (MRQ) | 13.68% |
| Current Ratio (MRQ) | 2.33 |
| Operating Cash Flow (TTM) | -644.94 M |
| Levered Free Cash Flow (TTM) | -394.10 M |
| Return on Assets (TTM) | -129.99% |
| Return on Equity (TTM) | -316.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Biohaven Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 2.25 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.96% |
| % Held by Institutions | 90.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bellevue Group Ag | 31 Dec 2024 | 2,040,853 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (Raymond James, 412.65%) | Buy |
| Median | 51.00 (248.60%) | |
| Low | 26.00 (UBS, 77.72%) | Buy |
| Average | 47.90 (227.41%) | |
| Total | 10 Buy | |
| Avg. Price @ Call | 14.14 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 17 Sep 2025 | 28.00 (91.39%) | Buy | 14.70 |
| UBS | 16 Sep 2025 | 26.00 (77.72%) | Buy | 13.49 |
| Raymond James | 03 Sep 2025 | 75.00 (412.65%) | Buy | 16.21 |
| BTIG | 19 Aug 2025 | 60.00 (310.12%) | Buy | 15.25 |
| B of A Securities | 12 Aug 2025 | 49.00 (234.93%) | Buy | 13.47 |
| Baird | 12 Aug 2025 | 52.00 (255.43%) | Buy | 13.47 |
| HC Wainwright & Co. | 12 Aug 2025 | 30.00 (105.06%) | Buy | 13.47 |
| Leerink Partners | 12 Aug 2025 | 50.00 (241.76%) | Buy | 13.47 |
| Morgan Stanley | 12 Aug 2025 | 54.00 (269.10%) | Buy | 13.47 |
| JP Morgan | 18 Jun 2025 | 55.00 (275.94%) | Buy | 14.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Sep 2025 | Announcement | Shareholders SueWallSt in New Class Action Against Biohaven Ltd. - Act Now |
| 09 Sep 2025 | Announcement | Investors SueWallSt as Biohaven Ltd. Faces Securities Fraud Allegations |
| 03 Sep 2025 | Announcement | Investors SueWallSt as Biohaven Ltd. Faces Securities Fraud Allegations |
| 02 Sep 2025 | Announcement | Shareholders SueWallSt in New Class Action Against Biohaven Ltd. - Act Now |
| 21 Aug 2025 | Announcement | Shareholders SueWallSt in New Class Action Against Biohaven Ltd. - Act Now |
| 11 Aug 2025 | Announcement | Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |